What the Cochrane Evidence Says About Vedolizumab for Crohn's Disease

When a person with Crohn's disease reaches the point where standard anti-inflammatory medications and immunosuppressants are no longer working, the next step is usually a biologic medicine. Vedolizumab is one of those options, and it has a distinctive feature that sets it apart from most of its predecessors: it is gut-selective, targeting the immune response specifically in the digestive tract rather than suppressing the immune system throughout the body.

A 2023 Cochrane systematic review and meta-analysis pooled the best available randomised trial data to assess how well vedolizumab works in Crohn's disease, both for getting symptoms under control and for keeping them there. This article explains what the review found, what the limitations are, and what the results mean for patients living with Crohn's.

What Crohn's Disease Is

Crohn's disease is a chronic inflammatory bowel condition that can affect any part of the digestive tract, from the mouth to the anus. The NHS describes it as a lifelong condition characterised by periods of active disease, during which symptoms including diarrhoea, abdominal cramps, fatigue, blood in the stool, and unintended weight loss are present, and periods of remission, during which those symptoms ease significantly or disappear. Unlike ulcerative colitis, which is confined to the colon and rectum, Crohn's can involve the small intestine, large intestine, or both, and can cause deeper, more penetrating inflammation.

Treatment typically begins with anti-inflammatory drugs such as corticosteroids and aminosalicylates, and progresses to immunosuppressants such as azathioprine or methotrexate. When those approaches fail, biologic medicines that target specific components of the immune response become the next option. It is in this setting that vedolizumab is most commonly used.

What Vedolizumab Is

Vedolizumab (brand name Entyvio) is a humanised monoclonal antibody that works by blocking a protein on certain immune cells called alpha-4 beta-7 integrin. This protein acts like a homing signal that directs white blood cells from the bloodstream into the gut, where they drive inflammation in conditions like Crohn's. By blocking it, vedolizumab reduces the migration of those cells into intestinal tissue, damping down the inflammatory response in the digestive tract.

The key characteristic that distinguishes vedolizumab from TNF-alpha inhibitors (such as infliximab and adalimumab) is its gut selectivity: because the mechanism targets a receptor found mainly in gut tissue, its immunosuppressive effect is concentrated in the intestine rather than the whole immune system. According to the Crohn's and Colitis Foundation, vedolizumab is FDA-approved for moderate-to-severely active Crohn's disease in adults.

Vedolizumab is administered as an intravenous infusion, usually at a hospital or infusion clinic. The standard schedule starts with infusions at weeks 0, 2, and 6 (the induction phase), followed by a maintenance dose once every eight weeks.

What the Cochrane Review Did

The 2023 Cochrane review (pubmed:37458279) followed the structured methodology Cochrane reviews are known for: a pre-specified search strategy across multiple databases, systematic inclusion and exclusion criteria for trials, independent risk-of-bias assessment, and statistical pooling of results across studies. The review was published in the Cochrane Database of Systematic Reviews, which is recognised as a Tier 1 source of evidence synthesis in clinical medicine.

The analysis focused on adults with moderate-to-severely active Crohn's disease who received vedolizumab (at the standard 300mg IV dose) or placebo in randomised controlled trials. The primary evidence base came from the GEMINI 2 trial, which was the pivotal RCT examining vedolizumab for both induction and maintenance in Crohn's disease, and the GEMINI 3 trial, which enrolled participants who had specifically failed or could not tolerate a TNF inhibitor. The review assessed outcomes at standard time points: early induction (around week 6), later induction (around week 10), and maintenance (around week 52).

What the Results Showed: Induction

For the induction phase, the Cochrane review found that vedolizumab was significantly more effective than placebo for both clinical remission and clinical response in Crohn's disease. However, an important nuance emerged from the timing of the assessments.

At week 6, the early induction time point, clinical remission rates with vedolizumab were modest: data from GEMINI 2, as reported in the review, showed approximately 14 to 15 percent of vedolizumab-treated participants achieving clinical remission at week 6, compared with around 7 percent in the placebo group. The difference was statistically significant, but the absolute numbers were low on both sides.

By week 10, response rates were more pronounced. The authors noted that vedolizumab has a slower onset of action in Crohn's disease than in ulcerative colitis, and that its clinical effect accumulates over the weeks and months of treatment. This is a pharmacological characteristic that matters practically: some patients and clinicians may interpret limited early improvement as treatment failure when the drug is still building its effect.

What the Results Showed: Maintenance

The evidence for maintenance was stronger. The Cochrane review found vedolizumab significantly more effective than placebo for maintaining clinical remission, clinical response, and endoscopic response at week 52.

The GEMINI 2 maintenance data, pooled in the review, showed approximately 36 to 39 percent of participants who continued vedolizumab every 8 weeks achieving clinical remission at one year, compared with roughly 22 percent in the placebo group. That difference translated to a meaningful advantage for vedolizumab. Endoscopic response, meaning improvement in the appearance of the bowel lining on colonoscopy, was also significantly better with vedolizumab than placebo at maintenance.

The reviewers characterised the maintenance evidence as more consistent and clinically convincing than the induction data, which is consistent with how the drug's mechanism of action plays out over time: the gut-selective immune dampening accumulates its effects gradually.

Safety: What the Review Found

The Cochrane review found that vedolizumab did not significantly increase the risk of adverse events, serious adverse events, or withdrawal from treatment due to side effects compared with placebo. Infection rates, which are a primary safety concern with biologic treatments given to immunocompromised patients, were not significantly higher with vedolizumab than with placebo in the pooled trial data.

This safety profile reflects the gut-selective mechanism. TNF-alpha inhibitors, which suppress a broader component of the immune response, carry a recognised risk of systemic infections, including serious ones. Because vedolizumab acts predominantly within gut tissue, it does not carry the same theoretical level of systemic immune suppression, and the trial data reviewed by the Cochrane authors supported that distinction. Longer-term real-world safety evidence continues to be accumulated in post-marketing registries, and patients should discuss individual risk with their care team.

Where Vedolizumab Stands Today

In the United Kingdom, NICE recommends vedolizumab as an option for treating moderately to severely active Crohn's disease in adults whose disease has not responded adequately to conventional therapy and who have also failed or could not tolerate a TNF inhibitor. This positioning places vedolizumab as a second-line biologic option in the UK, typically used after one or more TNF-alpha inhibitors have not achieved adequate disease control.

In other countries, including the United States, prescribing practice and treatment sequencing varies. Some guidelines now allow vedolizumab to be used earlier in the treatment pathway, particularly in patients for whom the gut-selective safety profile is a priority, such as those with a history of recurrent infections or for whom systemic immunosuppression carries greater risk.

What This Evidence Means for Patients

The Cochrane review provides patients with Crohn's disease with a reliable, high-quality summary of the trial evidence on vedolizumab. The overall picture is that vedolizumab works: it is significantly better than placebo for inducing and maintaining remission in Crohn's disease, with a safety profile that is notably favourable compared with treatments that act more broadly on the immune system.

The nuances matter too. The drug's slower onset means that patients starting vedolizumab for induction need to understand that the first few weeks may not produce the rapid relief some other treatments can achieve. For maintenance, the evidence is more straightforwardly positive. And the gut-selective mechanism, while a genuine clinical advantage for safety, does mean that vedolizumab is not expected to treat extraintestinal manifestations of Crohn's disease (such as skin or joint involvement) as effectively as systemic biologics.

For patients who have tried and not tolerated TNF inhibitors, or for whom infection risk is a particular concern, vedolizumab represents an option with a distinct and well-characterised evidence base.